Hillstream BioPharma Adds Leading Cancer Drug Development Executive and Features Hillstream’s Quatramer-Based Ferroptosis Inducer, HSB-1216, in Two Abstracts Available for Viewing at AACR 2021 Annual Meeting

March 11th, 2021

Lynne A. Bui M.D., leading cancer drug development executive, joins Hillstream BioPharma’s Board of Directors

 Abstracts highlight mechanistic and pharmacokinetic data from HSB-1216 in small cell lung cancer and in combination with ultra-low-dose chemotherapy in triple negative breast cancer

Bridgewater, NJ – March 11, 2021 – Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the progress of the Quatramer-based Ferroptosis Inducer, HSB-1216, are available as an e-poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting taking place from April 10-15 and May 17-21, 2021.

The accepted abstracts, available starting March 10, 2020 at 4:30pm ET, summarize non-clinical research using HSB-1216 in the significant unmet need indications of platinum-resistant small cell lung cancer as a single agent and in combination with doxorubicin in triple negative breast cancer.  “It is with great pleasure to welcome Lynne A. Bui, M.D. to Hillstream’s Board of Directors.  Dr. Bui brings a wealth of hands-on experience in oncology drug development from preclinical through registration which will be extremely beneficial as we advance our exciting pipeline,” stated Randy Milby, CEO of Hillstream BioPharma. “In addition, we are actively evaluating the potential utility of HSB-1216 in a variety of solid tumor types.”

Lynne A. Bui, M.D. is the Co-Founder and CEO of Khloris Biosciences, Inc., an iPSC-based cancer cell therapy company.  She is a board-certified hematologist oncologist, drug developer, seasoned entrepreneur, and angel investor.  She has unparalleled experience in basic, translational, and clinical research spanning over 15 years.  Her experience ranges from direct patient care and leading clinical development programs to preclinical IND enabling studies, as well as Phase 1 to 3 registration studies for multiple approved drugs. She has held senior level positions at Exelixis, Inc., Onyx Pharmaceuticals (acquired by Amgen in 2013 for $10 billion), and Intellikine Inc. (acquired by Takeda for $190 million upfront in 2011), and has experience with small molecules, antibodies, dendritic cell vaccines, gene therapies, embryonic stem cells, and cell therapies. She is also the Founder and Chairman of Global Cancer Research Institute (GCRI) and the GCRI Foundation. Dr. Bui received her M.D., internal medicine residency, and hematology/oncology fellowship training from the David Geffen UCLA School of Medicine. She received her B.A. in molecular and cellular biology with an emphasis in neurobiology from UC Berkeley.

The e-poster website will be launched April 10, 2021, the first day of the AACR Virtual Annual Meeting.  All e-posters will be made available for browsing on this date and will remain available for viewing through June 21, 2021. The two Hillstream BioPharma sponsored presentations include:

Abstract Number 3107: HSB-1216 A Novel Agent for the Treatment of Chemotherapy-Resistant ES-Small Cell Lung Cancer

  • Session Type: E-Poster Session
  • Session Category: Tumor Biology
  • Session Title: Stem Cells Biology

Abstract Number 3082: Synergistic Inhibition of TNBC cell growth by novel doxorubicin/salinomycin – encapsulated dual drug nanoparticles

  • Session Type: E-Poster Session
  • Session Category: Tumor Biology
  • Session Title: Stem Cells Biology

The two Hillstream BioPharma-sponsored abstracts will be published online in the Proceedings supplement to AACR journal, Cancer Research, after completion of the AACR Virtual Annual Meeting and will be accessible on the Hillstream website (tharimmune.com).

About HSB-1216
HSB-1216 is a novel and potent inducer of an emerging mechanism of cell death called ferroptosis.  This process allows HSB-1216 to cause lysosomal membrane permeabilization of hard-to-treat cancer cells – causing them to rupture and stop replicating.  The development of HSB-1216 is focused on a variety of solid tumors with high unmet need.  HSB-1216 leverages the Quatramer platform, a tumor-targeted platform with capacity to deliver drug and biologic combinations to solid tumors.  Quatramer enhances the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity.  Quatramer offers the potential to significantly improve the profile and widen the therapeutic window of HSB-1216 and other small molecules, peptides, cytokines and oligomers preferentially delivered to tumors. Quatramer building blocks are pH-triggered to degrade intracellularly.

About Hillstream BioPharma, Inc.
Hillstream BioPharma, Inc. (“Hillstream”, “Company”) is developing novel therapeutics targeting rare high-unmet need cancers. By leveraging its Quatramer tumor targeting platform and its Trident Computational Intelligence platform to help identify and develop novel therapeutics, Hillstream is building a pipeline of proprietary therapeutics for rare cancers.  Hillstream is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors encoding inflammatory cytokines, directly into the tumor microenvironment. We will work to improve the lives of patients as we rapidly move into the clinic to treat sarcomas, small cell lung cancer and other high unmet need rare cancers.  For more information, please visit tharimmune.com

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of

existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic.  Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

Hillstream BioPharma, Inc.
Randy Milby
Chief Executive Officer
Tel: +1.302.743.2995
Email: info@tharimmune.com
tharimmune.com

Investor Contact:
Jennifer K. Zimmons, Ph.D.
Investor Relations
Zimmons International Communications
Tel: +1 917.214.3514
Email: jzimmons@zimmonsic.com